Page last updated: 2024-10-25
cilostazol and Arterial Brain Diseases
cilostazol has been researched along with Arterial Brain Diseases in 2 studies
Research Excerpts
Excerpt | Relevance | Reference |
" The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 8.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
"To assess whether cilostazol, a phosphodiesterase III inhibitor, improves treadmill and community-based walking ability and health-related quality of life (HQL) in patients with intermittent claudication resulting from peripheral arterial disease (PAD)." | 8.81 | Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. ( Forbes, WP; Heckman, J; Hiatt, WR; McCarthy, WJ; Regensteiner, JG; Ware, JE; Zhang, P, 2002) |
" The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 4.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
"To assess whether cilostazol, a phosphodiesterase III inhibitor, improves treadmill and community-based walking ability and health-related quality of life (HQL) in patients with intermittent claudication resulting from peripheral arterial disease (PAD)." | 4.81 | Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. ( Forbes, WP; Heckman, J; Hiatt, WR; McCarthy, WJ; Regensteiner, JG; Ware, JE; Zhang, P, 2002) |
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
Qian, Y | 1 |
Bi, Q | 1 |
Regensteiner, JG | 1 |
Ware, JE | 1 |
McCarthy, WJ | 1 |
Zhang, P | 1 |
Forbes, WP | 1 |
Heckman, J | 1 |
Hiatt, WR | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status |
Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed |
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change From Baseline in Claudication Onset Time at Day 180
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
Intervention | Log Minutes (Mean) |
---|
Cilostazol + L-Carnitine | 1.065 |
Cilostazol + Placebo | 0.896 |
Change From Baseline in Claudication Onset Time at Day 90
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
Intervention | Log Minutes (Mean) |
---|
Cilostazol + L-Carnitine | 1.001 |
Cilostazol + Placebo | 0.815 |
Change From Baseline in Peak Walking Time (PWT) at Day 180
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
Intervention | Log Minutes (Mean) |
---|
Cilostazol + L-Carnitine | 0.241 |
Cilostazol + Placebo | 0.134 |
Change From Baseline in Peak Walking Time at Day 180
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
Intervention | Log Minutes (Mean) |
---|
Cilostazol + L-Carnitine | 0.267 |
Cilostazol + Placebo | 0.145 |
Change From Baseline in Peak Walking Time at Day 90
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
Intervention | Log Minutes (Mean) |
---|
Cilostazol + L-Carnitine | 0.166 |
Cilostazol + Placebo | 0.139 |
Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 180
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
Intervention | score on a scale (Mean) |
---|
Cilostazol + L-Carnitine | 13.20 |
Cilostazol + Placebo | 6.57 |
Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 90
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
Intervention | score on a scale (Mean) |
---|
Cilostazol + L-Carnitine | 12.98 |
Cilostazol + Placebo | 10.01 |
Reviews
2 reviews available for cilostazol and Arterial Brain Diseases